OCUGEN INC (OCGN) Fundamental Analysis & Valuation
NASDAQ:OCGN • US67577C1053
Current stock price
1.87 USD
-0.09 (-4.59%)
At close:
1.8701 USD
+0 (+0.01%)
After Hours:
This OCGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. OCGN Profitability Analysis
1.1 Basic Checks
- OCGN had negative earnings in the past year.
- In the past year OCGN has reported a negative cash flow from operations.
- In the past 5 years OCGN always reported negative net income.
- In the past 5 years OCGN always reported negative operating cash flow.
1.2 Ratios
- OCGN has a Return On Assets of -111.15%. This is in the lower half of the industry: OCGN underperforms 79.19% of its industry peers.
- With a Return On Equity value of -1812.06%, OCGN is not doing good in the industry: 81.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.15% | ||
| ROE | -1812.06% | ||
| ROIC | N/A |
ROA(3y)-106.4%
ROA(5y)-89.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- OCGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. OCGN Health Analysis
2.1 Basic Checks
- OCGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for OCGN has been increased compared to 1 year ago.
- OCGN has more shares outstanding than it did 5 years ago.
- OCGN has a worse debt/assets ratio than last year.
2.2 Solvency
- OCGN has an Altman-Z score of -5.33. This is a bad value and indicates that OCGN is not financially healthy and even has some risk of bankruptcy.
- OCGN has a worse Altman-Z score (-5.33) than 64.16% of its industry peers.
- OCGN has a Debt/Equity ratio of 8.04. This is a high value indicating a heavy dependency on external financing.
- OCGN has a Debt to Equity ratio of 8.04. This is amonst the worse of the industry: OCGN underperforms 81.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 8.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.33 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
- A Current Ratio of 1.85 indicates that OCGN should not have too much problems paying its short term obligations.
- OCGN has a worse Current ratio (1.85) than 78.42% of its industry peers.
- A Quick Ratio of 1.85 indicates that OCGN should not have too much problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 1.85, OCGN is doing worse than 77.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.85 |
3. OCGN Growth Analysis
3.1 Past
- The earnings per share for OCGN have decreased strongly by -21.05% in the last year.
- OCGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.83%.
- Measured over the past years, OCGN shows a very strong growth in Revenue. The Revenue has been growing by 156.17% on average per year.
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)8.83%
Revenue growth 3YN/A
Revenue growth 5Y156.17%
Sales Q2Q%-125.26%
3.2 Future
- Based on estimates for the next years, OCGN will show a very strong growth in Earnings Per Share. The EPS will grow by 51.18% on average per year.
- OCGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 215.00% yearly.
EPS Next Y-4.66%
EPS Next 2Y35.82%
EPS Next 3Y33.04%
EPS Next 5Y51.18%
Revenue Next Year-60.02%
Revenue Next 2Y250.97%
Revenue Next 3Y233.44%
Revenue Next 5Y215.01%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. OCGN Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for OCGN. In the last year negative earnings were reported.
- Also next year OCGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as OCGN's earnings are expected to grow with 33.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.82%
EPS Next 3Y33.04%
5. OCGN Dividend Analysis
5.1 Amount
- No dividends for OCGN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
OCGN Fundamentals: All Metrics, Ratios and Statistics
1.87
-0.09 (-4.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04 2026-03-04/bmo
Earnings (Next)05-07 2026-05-07
Inst Owners18.82%
Inst Owner Change22.28%
Ins Owners2.09%
Ins Owner Change45.4%
Market Cap613.17M
Revenue(TTM)4.41M
Net Income(TTM)-64.02M
Analysts81.82
Price Target9.18 (390.91%)
Short Float %15.82%
Short Ratio7.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.9%
Min EPS beat(2)-22.55%
Max EPS beat(2)14.75%
EPS beat(4)3
Avg EPS beat(4)3.39%
Min EPS beat(4)-22.55%
Max EPS beat(4)14.75%
EPS beat(8)7
Avg EPS beat(8)15.68%
EPS beat(12)9
Avg EPS beat(12)14.24%
EPS beat(16)10
Avg EPS beat(16)-204.99%
Revenue beat(2)2
Avg Revenue beat(2)248.45%
Min Revenue beat(2)212.3%
Max Revenue beat(2)284.59%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.33%
EPS NY rev (1m)0%
EPS NY rev (3m)4.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-29.89%
Revenue NY rev (3m)2.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 114.18 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 173.56 | ||
| P/tB | 173.56 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.02
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -111.15% | ||
| ROE | -1812.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-106.4%
ROA(5y)-89.86%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 8.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.82% | ||
| Cap/Sales | 3.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.85 | ||
| Altman-Z | -5.33 |
F-Score1
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)555.94%
Cap/Depr(5y)612.44%
Cap/Sales(3y)87.08%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
EPS Next Y-4.66%
EPS Next 2Y35.82%
EPS Next 3Y33.04%
EPS Next 5Y51.18%
Revenue 1Y (TTM)8.83%
Revenue growth 3YN/A
Revenue growth 5Y156.17%
Sales Q2Q%-125.26%
Revenue Next Year-60.02%
Revenue Next 2Y250.97%
Revenue Next 3Y233.44%
Revenue Next 5Y215.01%
EBIT growth 1Y3.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.87%
OCF growth 3YN/A
OCF growth 5YN/A
OCUGEN INC / OCGN Fundamental Analysis FAQ
What is the fundamental rating for OCGN stock?
ChartMill assigns a fundamental rating of 2 / 10 to OCGN.
What is the valuation status for OCGN stock?
ChartMill assigns a valuation rating of 1 / 10 to OCUGEN INC (OCGN). This can be considered as Overvalued.
What is the profitability of OCGN stock?
OCUGEN INC (OCGN) has a profitability rating of 0 / 10.
What is the financial health of OCUGEN INC (OCGN) stock?
The financial health rating of OCUGEN INC (OCGN) is 1 / 10.